Imzokitug

BIOLOGICAL2 trials

Sponsors

Mayo Clinic, Bristol-Myers Squibb

Conditions

Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung Cancer (NSCLC)Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8

Phase 2

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

RecruitingNCT07226856

Mayo ClinicMetastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Start: 2025-12-12End: 2028-12-01Target: 43Updated: 2026-06-09

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

RecruitingNCT07680764

Bristol-Myers SquibbLocally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start: 2026-08-31End: 2030-09-15Target: 160Updated: 2026-09-16